Streetbeat News

Stock Prices

CCCC

C4 Therapeutics is set to present preliminary Phase 1 clinical data for its CFT1946 monotherapy at the ESMO Congress 2024. This development is significant for the company's pipeline and future prospects.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:20 am

MGNX

MacroGenics, Inc. will present Phase 2 results of its cancer treatment, vobramitamab duocarmazine, at the ESMO 2024 Congress. This presentation could impact the company's stock as it showcases their progress in treating metastatic castration-resistant prostate cancer.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:15 am

NTRA

Natera, Inc. will present significant findings from the CIRCULATE-Japan trial at the ESMO 2024 Congress, highlighting a 10X survival advantage with its Signatera test. The presentations will include data on colorectal cancer, breast cancer, and squamous cell carcinoma.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:05 am

BIG

Big Lots, Inc. (NYSE:BIG) has filed for Chapter 11 bankruptcy and agreed to sell its assets to Nexus Capital Management. The company aims to continue operations during the process and has secured $707.5 million in financing. The economic climate, marked by high inflation and interest rates, has pressured Big Lots, leading to this decision.

Portfolio Pulse from Shanthi Rexaline

September 09, 2024 | 7:01 am

AAPL

ARM

Apple Inc. is set to launch the iPhone 16 series featuring ARM Holdings' next-gen AI chip technology, enhancing AI capabilities. The A18 chip, based on Arm's V9 architecture, will be unveiled at Apple's 'Glowtime' event. This move aligns with Apple's strategy to integrate advanced AI features into its products.

Portfolio Pulse from Ananya Gairola

September 09, 2024 | 6:29 am

PLTR

Palantir Technologies (NASDAQ:PLTR) will be added to the S&P 500 Index, marking a significant milestone for the company. Analyst Daniel Ives from Wedbush views this as a validation of Palantir's growth and profitability potential, driven by its AI platform and U.S. Commercial business. The inclusion is expected to boost Palantir's momentum, especially in the federal sector, and marks the start of a multi-year growth cycle. Wedbush has an Outperform rating and a $38 price target for Palantir.

Portfolio Pulse from Shanthi Rexaline

September 09, 2024 | 6:23 am

FBTC

Asian-origin Bitcoin and Ethereum ETFs in Hong Kong have underperformed due to market volatility and US regulatory uncertainty. The ChinaAMC Bitcoin ETF and Bosera HashKey Bitcoin ETF have seen declines, with Ethereum-based ETFs experiencing even larger losses. The US election season is contributing to market turbulence, affecting both Asian and US-based cryptocurrency funds.

Portfolio Pulse from Aniket Verma

September 09, 2024 | 6:13 am

AZN

IPHA

Innate Pharma and AstraZeneca presented preliminary data from the NeoCOAST-2 Phase 2 study at WCLC 2024, focusing on treatments for early-stage NSCLC. The study includes combinations of oleclumab, monalizumab, and datopotamab deruxtecan with durvalumab and chemotherapy.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:58 am

FXI

China's Producer Price Index (PPI) for August fell by 1.8% year-over-year, which is a larger decline than the estimated 1.5% and the previous month's 0.8% decrease. This indicates continued deflationary pressures in China's industrial sector.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:28 am

FXI

China's Consumer Price Index (CPI) for August increased by 0.6% year-over-year, slightly below the estimated 0.7% but above the prior 0.5%. This data may impact the performance of the iShares China Large-Cap ETF (FXI), which is sensitive to economic indicators from China.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 5:28 am